Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Longitudinal Observational Follow-up of the PRECEPT Study Cohort (PostCEPT)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2008 by The Parkinson Study Group.
Recruitment status was:  Enrolling by invitation
National Institute of Neurological Disorders and Stroke (NINDS)
H. Lundbeck A/S
Parkinson's Disease Foundation
United States Department of Defense
Information provided by:
The Parkinson Study Group Identifier:
First received: January 17, 2008
Last updated: March 26, 2008
Last verified: March 2008
The purpose of this study is to longitudinally follow consenting clinical trial participants who participated in PRECEPT (A Randomized, Double Blind, Placebo Controlled, Dose Finding Study to Assess the Efficacy and Safety of CEP 1347 in Patients With Early Parkinson's Disease). The study will assess the clinical and imaging outcomes relevant to the natural history of Parkinson's disease (PD), as well as determine early biomarkers of the disease.

Parkinson Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: A Longitudinal Observational Follow-up of the PRECEPT Study Cohort

Resource links provided by NLM:

Further study details as provided by The Parkinson Study Group:

Primary Outcome Measures:
  • Unified Parkinson Disease Rating Scale (UPDRS) and β-CIT SPECT imaging of the dopamine transporter. [ Time Frame: Annual, ongoing assessments ]

Secondary Outcome Measures:
  • University of Pennsylvania Smell Identification Test (UPSIT) [ Time Frame: Annual, ongoing assessments ]

Biospecimen Retention:   Samples With DNA
Whole blood

Estimated Enrollment: 530
Study Start Date: August 2006
Estimated Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Parkinson disease patients who participated in the PRECEPT clinical trial.

Inclusion Criteria:

  • Participation in the PRECEPT study
  • Willing and able to give informed consent

Exclusion Criteria:

  • Patients will be excluded from participating in the the study if either of the criteria stated above is not met
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00605163

  Show 55 Study Locations
Sponsors and Collaborators
The Parkinson Study Group
National Institute of Neurological Disorders and Stroke (NINDS)
H. Lundbeck A/S
Parkinson's Disease Foundation
United States Department of Defense
  More Information

Additional Information:
Responsible Party: Ira Shoulson, MD, Principal Investigator, University of Rochester Clinical Trials Coordination Center Identifier: NCT00605163     History of Changes
Other Study ID Numbers: U01NS050095_PostCEPT
NINDS 5 U01NS050095-02
U01NS050095 ( US NIH Grant/Contract Award Number )
Study First Received: January 17, 2008
Last Updated: March 26, 2008

Keywords provided by The Parkinson Study Group:
Parkinson disease, observational, longitudinal

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases processed this record on May 22, 2017